883001-24-9

Basic information

• Product Name: 7-Bromo-5-fluoro-3-methyl-1H-indole
• Synonyms: 7-Bromo-5-fluoro-3-methyl-1H-indole;7-Bromo-5-fluoro-3-methylindole;1H-Indole, 7-bromo-5-fluoro-3-methyl-
• CAS NO: 883001-24-9
• Molecular Formula: C₉H₇BrFN
• Molecular Weight: 228.06
• Mol File: 883001-24-9.mol

Chemical Properties

• Boiling Point: 323.788 °C at 760 mmHg
• Flash Point: 149.622 °C
• Appearance: /
• Density: 1.646
• Vapor Pressure: 0mmHg at 25°C
• Refractive Index: 1.658
• CAS DataBase Reference: 7-Bromo-5-fluoro-3-methyl-1H-indole(CAS DataBase Reference)
• NIST Chemistry Reference: 7-Bromo-5-fluoro-3-methyl-1H-indole(883001-24-9)
• EPA Substance Registry System: 7-Bromo-5-fluoro-3-methyl-1H-indole(883001-24-9)

Safety Data

• Hazardous Substances Data: 883001-24-9(Hazardous Substances Data)

Usage

Uses

Used in Organic Synthesis:
7-Bromo-5-fluoro-3-methyl-1H-indole is used as a key intermediate in organic synthesis for the creation of various complex organic molecules. Its unique structure allows for versatile chemical reactions, making it a valuable component in the synthesis of specialty chemicals and pharmaceuticals.
Used in Pharmaceutical Research:
In the pharmaceutical industry, 7-Bromo-5-fluoro-3-methyl-1H-indole is used as a building block for the development of new drugs. Its specific molecular structure can be modified to target specific biological pathways, potentially leading to the discovery of novel therapeutic agents.
Used in Material Development:
7-Bromo-5-fluoro-3-methyl-1H-indole also has potential applications in the development of new materials. Its unique chemical properties can be leveraged to create innovative materials with specific characteristics for use in various industries.
Safety Considerations:
It is crucial to handle 7-Bromo-5-fluoro-3-methyl-1H-indole with care due to its potential hazardous properties. It should be used in a controlled laboratory environment to ensure the safety of researchers and the integrity of the experiments. Proper safety protocols, including the use of personal protective equipment and adherence to chemical handling guidelines, are essential when working with 7-Bromo-5-fluoro-3-methyl-1H-indole.

InChI:InChI=1/C9H7BrFN/c1-5-4-12-9-7(5)2-6(11)3-8(9)10/h2-4,12H,1H3

Upstream product

• 700-36-7 2-bromo-4-fluoronitrobenzene 
• 13154-14-8 1-propenylmagnesium bromide 
• 344-18-3 2,6-dibromo-4-fluoroaniline 
• 1730-25-2 (E)-1-propenylmagnesium bromide 
• 946197-48-4 1-N-allyl-2,6-dibromo-4-fluoroaniline 

Downstream Products

• 882999-50-0 (2E)-3-(5-fluoro-3-methyl-1H-indol-7-yl)acrylic acid 
• 885226-14-2 4-(5-fluoro-3-methyl-1H-indol-7-yl)-phenylamine 
• 861238-35-9 [2H]-DG-041 
• 885225-87-6 7-bromo-1-(3,4-difluoro-benzyl)-5-fluoro-3-methyl-1H-indole 
• 1208065-10-4 C₁₇H₁₅BrFNO 
• 883000-78-0 7-bromo-1-(2,4-dichlorobenzyl)-5-fluoro-3-methyl-1H-indole 

Relevant articles and documents

QUINOXALINE DERIVATIVES

The present invention relates to compounds according to general formula (I), which act as modulators of the glucocorticoid receptor and can be used in the treatment and/or prophylaxis of disorders which are at least partially mediated by the glucocorticoid receptor.

FURTHER SUBSTITUTED TRIAZOLO QUINOXALINE DERIVATIVES

The present invention relates to compounds according to general formula (I) which act as modulators of the glucocorticoid receptor and can be used in the treatment and/or prophylaxis of disorders which are at least partially mediated by the glucocorticoid receptor.

SUBSTITUTED TRIAZOLO QUINOXALINE DERIVATIVES

The present invention relates to compounds according to general formula (I) which act as modulators of the glucocorticoid receptor and can be used in the treatment and/or prophylaxis of disorders which are at least partially mediated by the glucocorticoid receptor.

Design, synthesis and biological evaluation of renin inhibitors guided by simulated annealing of chemical potential simulations

We have applied simulated annealing of chemical potential (SACP) to a diverse set of ～150 very small molecules to provide insights into new interactions in the binding pocket of human renin, a historically difficult target for which to find low molecular

Development of a scalable process for DG-041, a potent EP3 receptor antagonist, via tandem heck reactions

DG-041 is a small molecule antagonist of the EP3 receptor for prostaglandin E2 that is in clinical development for treatment of peripheral artery disease (PAD). Originally produced using a six-step synthetic procedure, process optimization led to development of a four-step sequence that is readily scalable. The key step in the optimized sequence contains two sequential Heck reactions, involving an intramolecular Heck cyclization followed by an intermolecular Heck coupling, performed in one pot to produce a highly substituted indole core.

7-(ACRYLOYL) INDOLE COMPOSITIONS AND METHODS FOR MAKING AND USING SAME

The present invention is directed to pharmaceutical compositions of 7-(acryloyl) indoles, such as 4,5-Dichloro-thiophene-2-sulfonic acid [(E)-3-[1-(2,4-dichlorophenylmethyl)-5-fluoro-3-methyl-1H-indol-7-yl]-acryloyl]amide (DTSI). The invention is also dir

PROCESS FOR PREPARING 7-(ACRYLOYL)INDOLES

The present invention involves a process for preparing substituted indoles, such as DTSI involving two sequential cross-coupling reactions.

Sulfonamide peri-substituted bicyclics for occlusive artery disease

Acyl sulfonamide, peri-substituted, fused bicyclic ring compounds useful for the treatment or prophylaxis of a prostaglandin-mediated disease or condition are disclosed. The compounds are of the general formula A representative example is: